Merck, Inc.
🇺🇸United States
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)
Phase 2
Completed
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: V114 Lot 1Biological: V114 Lot 2Biological: Prevnar 13™
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1051
- Registration Number
- NCT02987972
- Locations
- 🇪🇸
Hospital Clinico Universitario de Santiago ( Site 0016), Santiago de Compostela, Spain
🇪🇸Unidad de Estudios e Investigacion IHP ( Site 0017), Sevilla, Spain
🇺🇸Premier Health Research Center, LLC ( Site 0035), Downey, California, United States
Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)
Phase 1
Terminated
- Conditions
- NeoplasmsColorectal Cancer
- Interventions
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 111
- Registration Number
- NCT02972034
- Locations
- 🇨🇦
Merck Canada, Kirkland, Quebec, Canada
🇺🇸Call for Information (Investigational Site 0002), Grand Rapids, Michigan, United States
🇺🇸Call for Information (Investigational Site 0001), Nashville, Tennessee, United States
Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Biological: vibostolimabBiological: pembrolizumab/vibostolimab coformulationBiological: pembrolizumab
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 470
- Registration Number
- NCT02964013
Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 282
- Registration Number
- NCT02956629
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
Phase 1
Completed
- Conditions
- Amnestic Mild Cognitive ImpairmentAlzheimer's DiseaseProdromal Alzheimer's Disease
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02910739
Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 184
- Registration Number
- NCT02906709
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
Phase 3
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 425
- Registration Number
- NCT02864394
Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
Phase 1
Completed
- Conditions
- NeoplasmsCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT02862457
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
Phase 3
Completed
- Conditions
- Heart FailureChronic Heart Failure With Reduced Ejection Fraction
- Interventions
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 5050
- Registration Number
- NCT02861534
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Phase 1
Recruiting
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Biological: Pembrolizumab/Vibostolimab coformulationOther: Dexamethasone 8 mg
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT02861573
- Locations
- 🇲🇽
MSD Comercializadora, S. de R.L. de C.V., Mexico City, Mexico
🇺🇸Call for Information (Investigational Site 0005), Los Angeles, California, United States
🇺🇸Call for Information (Investigational Site 2041), Aurora, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath